Trial Profile
A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs MG1 MA3 (Primary) ; Ad MAGEA3
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LANDMARK
- 09 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 03 Aug 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2023.
- 30 Jan 2023 Planned End Date changed from 30 Dec 2022 to 30 Jun 2023.